These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 12203779)

  • 1. Chromosome arm 16q in Wilms tumors: unbalanced chromosomal translocations, loss of heterozygosity, and assessment of the CTCF gene.
    Yeh A; Wei M; Golub SB; Yamashiro DJ; Murty VV; Tycko B
    Genes Chromosomes Cancer; 2002 Oct; 35(2):156-63. PubMed ID: 12203779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A widely expressed transcription factor with multiple DNA sequence specificity, CTCF, is localized at chromosome segment 16q22.1 within one of the smallest regions of overlap for common deletions in breast and prostate cancers.
    Filippova GN; Lindblom A; Meincke LJ; Klenova EM; Neiman PE; Collins SJ; Doggett NA; Lobanenkov VV
    Genes Chromosomes Cancer; 1998 May; 22(1):26-36. PubMed ID: 9591631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of chromosome arm 16q loss with loss of imprinting of insulin-like growth factor-II in Wilms tumor.
    Mummert SK; Lobanenkov VA; Feinberg AP
    Genes Chromosomes Cancer; 2005 Jun; 43(2):155-61. PubMed ID: 15761865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors.
    Yuan E; Li CM; Yamashiro DJ; Kandel J; Thaker H; Murty VV; Tycko B
    Mol Cancer Res; 2005 Sep; 3(9):493-502. PubMed ID: 16179496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency and timing of loss of imprinting at 11p13 and 11p15 in Wilms' tumor development.
    Brown KW; Power F; Moore B; Charles AK; Malik KT
    Mol Cancer Res; 2008 Jul; 6(7):1114-23. PubMed ID: 18644976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of 11q loss, trisomy 12, and possible 16q loss with loss of imprinting of insulin-like growth factor-II in Wilms tumor.
    Watanabe N; Nakadate H; Haruta M; Sugawara W; Sasaki F; Tsunematsu Y; Kikuta A; Fukuzawa M; Okita H; Hata J; Soejima H; Kaneko Y
    Genes Chromosomes Cancer; 2006 Jun; 45(6):592-601. PubMed ID: 16518847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Germline mutations of the POU6F2 gene in Wilms tumors with loss of heterozygosity on chromosome 7p14.
    Perotti D; De Vecchi G; Testi MA; Lualdi E; Modena P; Mondini P; Ravagnani F; Collini P; Di Renzo F; Spreafico F; Terenziani M; Sozzi G; Fossati-Bellani F; Radice P
    Hum Mutat; 2004 Nov; 24(5):400-7. PubMed ID: 15459955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic imprinting and Wilms' tumor.
    Moulton T; Chung WY; Yuan L; Hensle T; Waber P; Nisen P; Tycko B
    Med Pediatr Oncol; 1996 Nov; 27(5):476-83. PubMed ID: 8827077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.
    Grundy PE; Breslow NE; Li S; Perlman E; Beckwith JB; Ritchey ML; Shamberger RC; Haase GM; D'Angio GJ; Donaldson M; Coppes MJ; Malogolowkin M; Shearer P; Thomas PR; Macklis R; Tomlinson G; Huff V; Green DM;
    J Clin Oncol; 2005 Oct; 23(29):7312-21. PubMed ID: 16129848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of imprinting of insulin-like growth factor-II in Wilms' tumor commonly involves altered methylation but not mutations of CTCF or its binding site.
    Cui H; Niemitz EL; Ravenel JD; Onyango P; Brandenburg SA; Lobanenkov VV; Feinberg AP
    Cancer Res; 2001 Jul; 61(13):4947-50. PubMed ID: 11431321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multipoint analysis of human chromosome 11p15/mouse distal chromosome 7: inclusion of H19/IGF2 in the minimal WT2 region, gene specificity of H19 silencing in Wilms' tumorigenesis and methylation hyper-dependence of H19 imprinting.
    Dao D; Walsh CP; Yuan L; Gorelov D; Feng L; Hensle T; Nisen P; Yamashiro DJ; Bestor TH; Tycko B
    Hum Mol Genet; 1999 Jul; 8(7):1337-52. PubMed ID: 10369881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered expression of imprinted genes in Wilms tumors.
    Hubertus J; Lacher M; Rottenkolber M; Müller-Höcker J; Berger M; Stehr M; von Schweinitz D; Kappler R
    Oncol Rep; 2011 Mar; 25(3):817-23. PubMed ID: 21174059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of 11q and 16q in Wilms tumors is associated with anaplasia, tumor recurrence, and poor prognosis.
    Wittmann S; Zirn B; Alkassar M; Ambros P; Graf N; Gessler M
    Genes Chromosomes Cancer; 2007 Feb; 46(2):163-70. PubMed ID: 17099873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of heterozygosity mapping at chromosome arm 16q in 712 breast tumors reveals factors that influence delineation of candidate regions.
    Cleton-Jansen AM; Callen DF; Seshadri R; Goldup S; Mccallum B; Crawford J; Powell JA; Settasatian C; van Beerendonk H; Moerland EW; Smit VT; Harris WH; Millis R; Morgan NV; Barnes D; Mathew CG; Cornelisse CJ
    Cancer Res; 2001 Feb; 61(3):1171-7. PubMed ID: 11221848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CTCF gene mutations in invasive ductal breast cancer.
    Aulmann S; Bläker H; Penzel R; Rieker RJ; Otto HF; Sinn HP
    Breast Cancer Res Treat; 2003 Aug; 80(3):347-52. PubMed ID: 14503807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of heterozygosity at 7p in Wilms' tumour development.
    Powlesland RM; Charles AK; Malik KT; Reynolds PA; Pires S; Boavida M; Brown KW
    Br J Cancer; 2000 Jan; 82(2):323-9. PubMed ID: 10646884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 16q heterozygosity loss in Wilms' tumour in children and its clinical importance.
    Skotnicka-Klonowicz G; Rieske P; Bartkowiak J; Szymik-Kantorowicz S; Daszkiewicz P; Debiec-Rychter M
    Eur J Surg Oncol; 2000 Feb; 26(1):61-6. PubMed ID: 10718182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathologic correlates of loss of heterozygosity in Wilm's tumor: a preliminary analysis.
    Grundy P; Telzerow P; Moksness J; Breslow NE
    Med Pediatr Oncol; 1996 Nov; 27(5):429-33. PubMed ID: 8926924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of heterozygosity at chromosome 16q in prostate adenocarcinoma: identification of three independent regions.
    Latil A; Cussenot O; Fournier G; Driouch K; Lidereau R
    Cancer Res; 1997 Mar; 57(6):1058-62. PubMed ID: 9067271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome-wide loss of heterozygosity analysis of WT1-wild-type and WT1-mutant Wilms tumors.
    Ruteshouser EC; Hendrickson BW; Colella S; Krahe R; Pinto L; Huff V
    Genes Chromosomes Cancer; 2005 Jun; 43(2):172-80. PubMed ID: 15761866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.